Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting.

Laura MartelliAnthony LopezSophie StrobelSilvio DaneseXavier RoblinCédric BaumannLaurent Peyrin-Biroulet

Published in: Journal of digestive diseases (2018)

The overall non-adherence rate for IFX use was 54.3%. Professional constraints and intentional non-adherence were the leading causes of non-adherence. Perineal disease and active CD were negatively related to adherence.

Keyphrases

end stage renal disease
glycemic control
chronic kidney disease
ejection fraction
peritoneal dialysis
metabolic syndrome
insulin resistance
nk cells